97179 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
#302METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES
#303BK VIRUS SEROLOGY ASSESSMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK
#304Antibody which specifically reacts with human integrin A6B4
#305Diagnostic markers for multiple sclerosis
#306Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
#307COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
#308Method for generating an affinity reagent library
#309Integrin αvβ8 neutralizing antibody
#310Methods of controlling the formation of disulfide bonds in protein solutions
#311Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#312Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin
#313PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES
#314Methods and arrays for use in the same
#315Anti-alpha V beta 6 antibodies and uses thereof
#316Anti-alpha V beta 6 antibodies and uses thereof
#317TREATMENT AND PREVENTION OF ACUTE KIDNEY INJURY USING ANTI-ALPHA V BETA 5 ANTIBODIES
#318Antibodies to integrin AVB6 and use of same to treat cancer
#319METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES
#320MAC-1 ANTIBODIES AND USES THEREOF
#321Methods and compositions related to modulators of eukaryotic cells
#322Methods for diagnosing and treating inflammatory bowel disease
#323MATERIALS AND METHODS RELATING TO MODIFYING THE BINDING OF ANTIBODIES
#324CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION
#325Immunoparticles and methods of generating and using same
#326Generating targeted sequence diversity in fusion proteins
#327Fc variant antibodies and their uses
#328Process for preparing purified drug conjugates
#329Antibodies Directed To Alpha V Beta 6 And Uses Thereof
#330ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#331Anti-αβantibodies
#332METHODS FOR DIAGNOSING AND TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
#333Methods of using an alpha-4-beta-7 heterodimer specific antagonist antibody
#334Liquid pharmaceutical formulations for injection comprising procaine and uses thereof
#335Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
#336Liquid pharmaceutical formulations for injection comprising thiamine pyrophosphate 1-(3-aminopropyl)-2-methyl-1H-imidazole and uses thereof
#337Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof
#338Methods and products for evaluating an immune response to a therapeutic protein
#339Fibrosis suppression by inhibiting integrin α-8 β-1 function
#340STEROID SPARING AGENTS AND METHODS OF USING SAME
#341IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF
#342Treatment of macrophage-related disorders
#343Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
#344Formulation for anti-α4β7 antibody
#345CHOLESTEROL-BASED MEDIA SUPPLEMENTS FOR CELL CULTURE
#346POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
#347Formulation for anti-α4β7 antibody
#348IN SILICO AFFINITY MATURATION
#349Administration of alpha4beta7 hetero-dimer-specific antibody
#350Anti-Alpha(v)Beta(6) Antibodies and Uses Thereof
#351Antibodies that bind integrin alpha-V beta-8
#352METHOD OF ADMINISTERING AN ANTIBODY
#353Method for the treatment of inflammatory disorders
#354SOLUBLE INTEGRIN ALPHA-4 MUTANT
#355Generation of new pancreatic beta cells
#356METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
#357Monoclonal antibody capable of binding integrin alpha 10 beta 1
#358Chemically Programmed Vaccination
#359Multivalent and Monovalent Multispecific Complexes and Their Uses
#360MIA (Melanoma Inhibitory Activity) Inhibitors for Detecting, Preventing and Curing Vitiligo
#361Alpha-4-beta-7 heterodimer specific antagonist antibody
#362Humanized anti-beta7 antagonists and uses therefor
#363Vitronectin:keratinocyte growth factor chimeras
#364Antibodies for the detection of integrin complexes in FFPE material
#365Antibodies directed to αVβ6 and uses thereof
#366Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same
#367Integrin heterodimer and a subunit thereof
#368Anti-human α9 integrin antibody and use thereof
#369TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES
#370Integrin α-Vβ8 neutralizing antibody
#371Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin
#372Anti-alpha2 integrin antibodies and their uses
#373MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF
#374Methods of treating inflammatory disorders using high concentration natalizumab compositions
#375INHIBITION OF LEUKOCYTE ADHESION
#376Immunoglobulin formulation and method of preparation thereof
#377Methods and compositions for treating and preventing disease associated with αvβ5 integrin
#378Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
#379FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#380ANTI-ALPHA V BETA 6 ANTIBODIES
#381TREATMENT OF RENAL DISEASES
#382Humanized anti-beta7 antagonists and uses therefor
#383Methods and products for evaluating an immune response to a therapeutic protein
#384Alpha-4-beta-7 heterodimer specific antagonist antibody
#385Alpha-4-beta-7 heterodimer specific antagonist antibody
#386Methods of treating inflammatory and autoimmune diseases with natalizumab
#387Antibodies for the detection of integrin complexes in FFPE material
#388Integrin Heterodimer And A Subunit Thereof
#389ANTIBODY FORMULATIONS
#390TREATMENT OF MACROPHAGE-RELATED DISORDERS
#391INTEGRIN HETERODIMER AND AN ALPHA SUBUNIT THEREOF
#392Method for the treatment of inflammatory disorders
#393ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES
#394CELL ADHESION INHIBITOR AND APPLICATIONS THEREOF
#395Monoclonal antibody capable of binding integrin alpha 10 beta 1
#396Method of Administering an Antibody
#397Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6
#398Anti-human α9 integrin antibody and use thereof
#399Inhibitors of angiopoietin-like 4 protein, combinations, and their use
#400Chemically programmed vaccination
#401Anti-αβantibodies and uses thereof
#402Generation, expression and characterization of the humanized K33N monoclonal antibody
#403AMINO ACID SEQUENCES DIRECTED AGAINST INTEGRINS AND USES THEREOF
#404POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
#405Compositions and Methods for Inhibiting Growth of SMAD-4 Deficient Cancers
#406Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6
#407Anti-alpha V immunoliposome compositions, methods and uses
#408Binding agents to the Integrin Alpha-11 subunit, and uses thereof
#409Methods and compositions for diagnosing and treating diseases
#410METHODS OF INHIBITING TUMOR GROWTH USING BETA 5 INTEGRIN ANTAGONISTS
#411Use of Agonists of Integrin Alpha 5 for Inducing the Osteogenic Differentiation of Mesenchymal Stem Cells
#412PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES
#413SENESCENCE CONTROL COMPOSITION CONTAINING EXTRACELLULAR MATRIX COMPONENTS, AND SENESCENCE CONTROL METHOD FOR SENESCENT CELLS USING SAME
#414Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
#415Alpha 5 beta 1 and its ability to regulate the cell survival pathway
#416Targeted Coagulation Factors and Method of Using the Same
#417ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#418Humanized anti-human α9-integrin antibody
#419Rationally-designed anti-αβν6 integrin antibody MFEVP1 and variants thereof, method of making such antibody and the use thereof in treating and diagnosis of disease
#420Process for preparing purified drug conjugates
#421Human anti-α9 integrin antibody
#422HUMANIZED ANTI-HUMAN ALPHA 9-INTEGRIN ANTIBODY
#423Antibodies directed to αVβ6 and uses thereof
#424Humanized anti-α 9 integrin antibodies and the uses thereof
#425Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
#426Nucleic Acids Encoding Humanized Immunoglobulin That Binds Alpha4Beta7 Integrin
#427IBUDILAST AND IMMUNOMODULATORS COMBINATION
#428USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
#429Alpha-4 beta-7 heterodimer specific antagonist antibody
#430VESICULAR PHOSPHOLIPID GELS COMPRISING PROTEINACEOUS SUBSTANCES
#431Methods of treating inflammatory and autoimmune diseases with natalizumab
#432Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
#433Methods of using angiopoietin-like 4 protein to stimulate proliferation of pre-adipocytes
#434Treatment with anti-alpha2 integrin antibodies
#435METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTRATION OF ALPHA-FETOPROTEIN IN COMBINATION WITH AN INTEGRIN ANTAGONIST
#436COMBINATION AND TREATMENT FOR MULTIPLE SCLEROSIS
#437Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue
#438Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
#439USE OF INTEGRIN ALPHA 10 BINDING ANTIBODY TO MODULATE EXTRACELLULAR MATRIX (CARTILAGE) TURNOVER
#440Immunoglobulin formulation and method of preparation thereof
#441Method for the treatment of inflammatory disorders
#442Methods and compositions for treating and preventing disease associated with αVβ5 integrin
#443Antihuman α9 integrin antibody and use of the same
#444Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
#445Humanized anti-beta7 antagonists and uses therefor
#446Methods of inhibiting amyloid toxicity
#447Anti-integrin antibodies, compositions, methods and uses
#448Lyophilized Immunoglobulin Formulations and Methods of Preparation
#449Anti-integrin antibodies, compositions, methods and uses
#450Anti-αβantibodies
#451Integrin Heterodimer and an Alpha Subunit Thereof
#452Monoclonal antibody capable of binding integrin alpha 10 beta 1
#453Methods and products for evaluating an immune response to a therapeutic protein
#454Anti-Alpha V Immunoliposome Composition, Methods, and Uses
#455Method for Preparing Antibody Conjugates
#456ANTI-ANGIOGENIC PROTEINS AND FRAGMENTS AND METHODS OF USE THEREOF
#457TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6
#458Humanized immunoglubulin reactive with alph4beta7 integrin
#459Inhibition of Tumorigenesis by Inhibition of a6b4 Integrin
#460Compositions and methods for inhibiting growth of smad4-deficient cancers
#461ANTIBODY FORMULATIONS
#462Anti-αβantibodies and uses thereof
#463POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION
#464Inhibition of leukocyte adhesion
#465Methods of treating cognitive impairment
#466Anti-α9 integrin antibody and the use thereof
#467Antibodies Directed to AlphaVBeta6 and Uses Thereof
#468Humanized anti-beta7 antagonists and uses therefor
#469Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
#470Methods of treating inflammatory and autoimmune diseases with natalizumab
#471Methods of treating inflammatory and autoimmune diseases with natalizumab
#472Mucosal vascular addressins and uses thereof
#473Treatment of acute lung injury, fibrosis and metastasis with antagonists of αvβ6
#474Anti-integrin antibodies, compositions, methods and uses
#475Humanized immunoglobulin reactive with alpha4beta7 integrin
#476Novel compounds
#477Methods for controlling pathological angiogenesis by inhibition of a6b4 integrin
#478Plant production of immunoglobulins with reduced fucosylation
#479Compositions and methods of using angiopoietin-like 4 protein
#480Process for preparing purified drug conjugates
#481Inhibitors of angiopoietin-like 4 protein, combinations, and their use
#482Administration of agents for the treatment of inflammation
#483Humanized immunoglobulin reactive with α4β7 integrin
#484Methods for inhibition of angiogenesis
#485Method for generating variable domain sequences of heavy chain antibodies
#486Method for generating variable domain sequences of heavy chain antibodies
#487Polypeptide variants with altered effector function
#488Antibody to an integrin heterodimer and/or a subunit thereof
#489Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
#490Anti-integrin immunoconjugates, methods and uses
#491Monoclonal antibody capable of binding integrin alpha 10 beta 1
#492Humanized anti-VLA4 immunoglobulins
#493Inhibitors of angiopoietin-like 4 protein, combinations, and their use
#494Compositions and methods of using angiopoietin-like 4 protein antibody
#495Humanized anti-beta7 antagonists and uses therefor
#496Mucosal vascular addressins and uses thereof
#497Alpha 5 beta 1 and its ability to regulate the cell survival pathway
#498Steroid sparing agents and methods of using same
#499High-sensitivity chemiluminescent ELISA prion detection method
#500Method for the treatment of fibrosis
#501Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
#502Novel integrin alpha subunit and uses thereof
#503Steroid sparing agents and methods of using same
#504Methods and composition for treating tumors and metastatic disease
#505Anti-αβantibodies
#506Polypeptide variants with altered effector function
#507Method for the treatment of inflammatory disorders
#508Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin
#509Methods for altering protein production rates
#510Polypeptide variants with altered effector function
#511Methods of treating sickle cell disease
#512Anti-angiogenic uses of IL-6 antagonists
#513Method of administering an antibody
#514Immunoglobulin formulation and method of preparation thereof
#515Methods of screening for monoclonal antibodies with desirable activity
#516Methods for humanizing rabbit monoclonal antibodies
#517Inhibitors of RIPK2 and medical uses thereof
#518Dosing regimen for treating inflammatory bowel disease
#519Autoinjector comprising high concentration formulation of vedolizumab
#520Methods for determining clinical response to TNF-alpha and/or JAK inhibitors in subjects with inflammatory diseases